Clinical Trials · NCT01652716
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 377
- Start date
- Jan 2013
- Locations
- 58 sites, United States
- Primary endpoint
- Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28